What is the revenue and EPS growth rate for Balchem year over year?

What factors drove the changes in Balchem's revenue and profit?

What were the key takeaways from Balchem's earnings call?

What does Balchem do and what are its main business segments?

Did Balchem beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Balchem next quarter?

What were the key takeaways from Balchem’s earnings call?

What is Balchem's latest dividend and current dividend yield?

- **Record Year Achieved**: Balchem surpassed $1 billion in annual sales for the first time, with 8.8% YoY growth and 9.8% EBITDA expansion.
- **Segment Strength**: Human Nutrition & Health led with 12.7% sales growth, driven by better-for-you food trends and international expansion.
- **Clinical Trial Momentum**: A Phase 2 study on choline and Alzheimer's disease is expected in 2026, with potential to unlock new health claims.
- **Sustainability Success**: Exceeded 2030 GHG reduction target, cutting emissions by 31% since 2020.
- **Financial Health**: 0.3x net debt leverage and $75 million cash on hand highlight strong balance sheet.

**【CEO Summary Section】**
- **Record Financial Performance**: Full-year 2025 sales reached $1.037 billion (+8.8% YoY), with adjusted EBITDA of $275 million (+9.8% YoY) and free cash flow of $174 million. Q4 2025 sales were $264 million (+9.8% YoY), with net income of $39 million (+16.8% YoY) and EPS of $1.21 (+17.5% YoY).
- **Segment Growth**: All three segments (Human Nutrition & Health, Animal Nutrition & Health, Specialty Products) delivered year-over-year growth. Human Nutrition & Health led with 12.7% sales growth, driven by better-for-you food trends and international expansion.
- **Strategic Initiatives**: Expanded marketing partnerships (e.g., New York Jets, Bayern Munich) to promote VitaCholine and K2VITAL. Advanced clinical research pipeline with 20 active studies, including a Phase 2 trial on choline and Alzheimer's disease.
- **Sustainability Progress**: Reduced greenhouse gas emissions by 31% (vs. 2020 baseline), exceeding 2030 goal, and water usage by 16%.

**【CFO Financial Commentary】**
- **Q4 Financials**: Gross margin dollars rose 8.8% to $94 million, while operating expenses increased 7% due to compensation. Adjusted EBITDA was $68 million (+8.1% YoY). Cash flow from operations was $67 million, ending with $75 million in cash.
- **Segment Breakdown**: Human Nutrition & Health earnings grew 8.9% to $37 million; Animal Nutrition & Health rose 8.6% to $6 million; Specialty Products increased 5.5% to $11 million.
- **Capital Deployment**: Repurchased 685,000 shares ($158 avg price) and raised dividend 10% to $0.96/share. Net debt reduced to $89 million (0.3x leverage ratio).

**【Q&A Highlights】**
- **Tariff Mitigation**: 2025 tariff impact was $10 million, managed via alternate supply chains and pricing. 2026 outlook: Minimal disruption expected, with $20 million theoretical max impact.
- **FX Exposure**: U.S. dollar-euro fluctuations contributed 0.7% to 2025 growth. No hedging planned for now.
- **Clinical Trials**: Phase 2 choline study at MD Anderson/MIT expected in 2026. Positive results could enable claims for adult cognition benefits.
- **Share Repurchases**: Focused on offsetting dilution and returning capital, with 685K shares bought in 2025.
- **Tax Rate**: 23% effective rate for 2026 modeling, consistent with historical range.

Balchem Corporation (BCPC) Q4 2025 Earnings Call Transcript

- **Record Q3 Financials**: $268M revenue (+11.5% YoY), $44M adjusted net earnings (+19.1% YoY), and $71M EBITDA (+11% YoY).
- **Segment Strength**: Human Nutrition & Health up 14.3%, Specialty Products up 7.5%, driven by better-for-you trends and geographic expansion.
- **Strategic Initiatives**: New manufacturing plant to double encapsulation capacity; European antidumping duties on choline set to boost market share.
- **Growth Drivers**: 25+ quarters of EBITDA growth, strong free cash flow ($51M), and minimal leverage (0.3x net debt).

**【CEO Opening Remarks】**
- Reported record Q3 2025 revenue of $268M (+11.5% YoY), driven by growth in all three segments.
- Achieved 25 consecutive quarters of adjusted EBITDA growth, with Q3 EBITDA at $71M (+11% YoY).
- Highlighted strong demand in Human Nutrition & Health (HMH) segment (+14.3% YoY) and Specialty Products (+7.5% YoY).
- Announced completion of NIH-funded choline biomarker study, validating plasma choline as a dietary adequacy indicator.
- Expanded marketing reach through Real Science Exchange platform, including new companion animal sector content.

**【CFO Financial Commentary】**
- GAAP net income: $40M (+19.1% YoY), EPS: $1.24 (+20.4% YoY).
- Adjusted net earnings: $44M (+19.1% YoY), adjusted EPS: $1.35 (+19.5% YoY).
- Gross margin: $95M (+11.8% YoY), margin rate: 35.7% (flat YoY).
- Operating expenses: $41M (+10.8% YoY) due to higher professional services and compensation.
- Free cash flow: $51M, net debt: $89M (leverage ratio 0.3x).
- Segment performance:
  - HMH: $174M (+14.3% YoY), EBITDA: $44M (+13.2% YoY).
  - Animal Nutrition: $56M (+6.6% YoY), EBITDA: $4M (+5.2% YoY).
  - Specialty Products: $36M (+7.5% YoY), EBITDA: $13M (+8.8% YoY).

**【Q&A Highlights】**
- **Food Ingredients Growth**: Driven by better-for-you trends (high protein, low sugar) and new product formulations. 2026 outlook: sustained growth as trends accelerate.
- **Nutrient Penetration**: Choline, K2, MSM markets still <10% penetrated; long-term growth runway supported by scientific validation.
- **European Antidumping Duties**: Preliminary 95-120% duties on Chinese choline expected to become final by end-2025, boosting European market share.
- **New Manufacturing Facility**: $100M Orange County plant to double encapsulation capacity, set to begin production mid-2027.
- **Debt Repayment**: Maintain disciplined cash deployment, prioritizing debt reduction while monitoring M&A opportunities.
- **Specialty Products Expansion**: Plant Nutrition growing 13% YoY via Latin America and Asia-Pacific expansion; Performance Gases stable at 7% YoY growth.

Balchem Corporation (BCPC) Q3 2025 Earnings Call Transcript

- **Record Q2 Growth**: 9.1% revenue rise to $255M, driven by 8.7% Human Nutrition, 13.1% Animal Nutrition, and 6% Specialty Products.
- **Choline Tariff Win**: 95%-120% EU duties on Chinese choline set to restore fair competition in Animal Nutrition.
- **$36M Expansion**: New NY facility to double microencapsulation capacity, enabling 20-25% annual growth in Food Ingredients.
- **Clinical Breakthroughs**: Choline linked to 51% Alzheimer's risk reduction; OptiMSM shown to accelerate muscle recovery post-exercise.
- **Strong Margins**: Adjusted EBITDA margin 27.1%, up 50bps YoY, with $41M free cash flow.


**【CEO Opening Remarks】**
- Q2 2025 revenue reached $255 million, up 9.1% YoY, with record performance across all segments (Human Nutrition & Health +8.7%, Animal Nutrition & Health +13.1%, Specialty Products +6%).
- Highlighted the European Commission's provisional 95%-120% antidumping duties on Chinese choline, expected to level the playing field and boost Animal Nutrition margins.
- Announced a $36 million microencapsulation facility in NY to double capacity, supporting 20%-25% annual growth in the Food Ingredients business.
- Emphasized strong demand for science-backed nutrients like VitaCholine (Alzheimer's study showing 51% risk reduction) and OptiMSM (exercise recovery benefits).

**【CFO Financial Commentary】**
- GAAP net income: $38 million (+19.4% YoY), EPS: $1.17 (+19.4% YoY).
- Adjusted EBITDA: $69 million (+11.2% YoY), margin: 27.1% (up 50bps YoY).
- Human Nutrition: $161 million (+8.7% YoY), driven by K2Vital (+30-40%), MSM (+20%), and encapsulated acids (+20%).
- Animal Nutrition: $56 million (+13.1% YoY), ruminant up 30% vs. monogastric +7%.
- Specialty Products: $37 million (+6% YoY), led by Performance Gases and Plant Nutrition.
- Free cash flow: $41 million, net debt: $125 million (leverage ratio 0.5x).

**【Q&A Highlights】**
- **Tariffs Impact**: $25 million annual cost, half offset by supply chain shifts, rest via pricing. No material impact on 2025 outlook.
- **New Facility Timeline**: Construction starts 2025H2, production late 2027-2028. Funded via existing cash and debt, no capex increase.
- **Human Health Strategy**: Expanding into medical foods/nutraceuticals with VitaCholine in multivitamins and choline in nutritional beverages.
- **Debt Reduction**: Steady paydown with free cash flow (~$40 million/year), no acceleration planned.
- **CureMark Update**: FDA BLA preparation ongoing, no timeline for filing.
- **Segment Growth Drivers**: Ruminant (AminoShure-XL), Specialty Gases, and encapsulated acids outpacing monogastric choline.


Balchem Corporation (BCPC) Q2 2025 Earnings Call Transcript

- **Record Q1 Performance**: $251M revenue (+4.5% YoY), $66M EBITDA (+8.9% YoY), all segments grow.
- **Trade Resilience**: 85% intra-regional sales, $20M tariff impact mitigated via supply chain and pricing.
- **Currency Tailwind**: Euro weakness could add $10-15M annualized revenue.
- **Growth Drivers**: Food Ingredients (+3.7%), Animal Nutrition EBITDA +154%, Specialty Products +16.9%.
- **Key Initiatives**: New product launches (AminoShure-XL, K2 DELTA), $31M free cash flow, 0.5x leverage ratio.
- **Upcoming Events**: Conferences in Paris, Chicago, and NY; Q2 earnings July 2025.

**【CEO Opening Remarks】**
- Q1 2025 revenue reached $251 million, up 4.5% YoY, with all segments (Human Nutrition & Health, Animal Nutrition & Health, Specialty Products) showing growth.
- Adjusted EBITDA hit a record $66 million (+8.9% YoY), driven by strong demand across end markets.
- Global trade environment: 85% of sales are intra-regional, minimizing China reliance; $100M annual raw material imports face $20M tariff impact, half mitigated via supply chain shifts, half via pricing.
- Resilient cash flow: $31M free cash flow, $50M cash on hand, net debt of $140M (0.5x leverage ratio).

**【CFO Financial Breakdown】**
- **Human Nutrition & Health**: $158M sales (+3.7% YoY), EBITDA $38M (+14.2% YoY), driven by Food Ingredients and Nutrients growth.
- **Animal Nutrition & Health**: $57M sales (+6.2% YoY), EBITDA $5M (+154% YoY), recovery in ruminant markets and new product launches (AminoShure-XL).
- **Specialty Products**: $33M sales (+5.3% YoY), EBITDA $10M (+16.9% YoY), strong Performance Gases demand.
- Gross margin improved 120bps to 35.2%, due to favorable product mix.

**【Q&A Key Takeaways】**
- **Tariff Mitigation**: 50% of $20M tariff impact offset via alternative suppliers; pricing actions cover remaining 50%.
- **Currency Impact**: Euro/USD weakening could add $10-15M annualized revenue tailwind; transactional FX impact negligible.
- **Product Pipeline**: VitaCholine Pro-Flo and K2 DELTA fermented showing early traction; meat encapsulation products growing >20% YoY.
- **Debt Strategy**: Focus on M&A and organic growth; share buybacks may resume if dilution exceeds thresholds.
- **Tax Rate**: Expect 22-22.5% for 2025, consistent with Q1 rate of 22.7%.

**【Forward Outlook】**
- Q2 2025 earnings call scheduled for late July; management confident in maintaining long-term growth trajectory despite macro uncertainties.
- Upcoming conferences: Deutsche Bank (Paris, June 4), Wells Fargo (Chicago, June 11), CJS Summer Conference (NY, July 10).

Balchem (BCPC)-24 Apr 25-2025 Q1 Earnings call transcript

- **Q4 Record Results**: $240M revenue (+4.9%), $63M EBITDA (+13.4%). Full year free cash flow $147M, debt reduced to 0.6x.
- **Product Innovation Payoff**: 3 new launches in HNH, AminoShure-XL driving ANH recovery. Partnerships with NFL and Bayern Munich boost brand equity.
- **Sustainability & Dividend Growth**: 15% water reduction vs. 2030 goal. 10% dividend increase to $0.87/share, 16th straight year of growth.
- **2025 Growth Drivers**: HNH nutrients and food solutions, Specialty Products expansion, ANH ruminant market recovery. Watch for tariff impacts on <5% of sales.

**【CEO Opening Remarks】**
- **Record Q4 and Full Year Performance**: Q4 revenue of $240M (+4.9% YoY), full year sales of $954M (+3.4% YoY). All segments achieved growth, with Human Nutrition & Health and Specialty Products leading.
- **Profitability Highlights**: Q4 adjusted EBITDA of $63M (+13.4%), full year adjusted EBITDA of $250M (+8.4%). Free cash flow of $147M reduced net debt to 0.6x.
- **Strategic Wins**: 3 new product launches in Human Nutrition (K2VITAL DELTA, VitaCholine Pro-Flo, Optifolin+), AminoShure-XL in Animal Nutrition. Partnerships with New York Jets and Bayern Munich Women's Team to boost brand awareness.
- **Sustainability Progress**: 15% water withdrawal reduction vs. 2020 baseline, ahead of 2030 goals. Dividend increased 10% to $0.87/share, 16th consecutive year of growth.

**【CFO Financial Breakdown】**
- **Revenue by Segment**: Human Nutrition ($147M, +6.8%), Animal Nutrition ($58M, +0.3%), Specialty Products ($33M, +6%).
- **Margin Expansion**: Gross margin 36% (up 320bps YoY), adjusted EBITDA margin 26.2% (up 200bps). Operating expenses $39M (+6.1%) due to transaction costs and compensation.
- **Liquidity**: $50M cash on hand, debt reduced by $37M in Q4. GAAP net income $34M (+26%), EPS $1.03 (+25.6%).

**【Q&A Key Takeaways】**
- **Human Nutrition Growth Drivers**: Nutrients (+5%), Food Ingredients (+7%) balanced growth. K2VITAL DELTA and encapsulated products outperformed.
- **Animal Nutrition Recovery**: Ruminant sales (+10% QoQ) drove modest YoY growth. AminoShure-XL adoption accelerating. Monogastric market remains flat due to European trade issues.
- **Tariff Risks**: <5% of sales exposed to China/Mexico tariffs. Diversified supply chain limits impact. Watchlist includes Canada ($30M sales).
- **M&A Activity**: Increased deal flow, but no immediate opportunities. Focus on strategic fits in health/nutrition space.
- **Bird Flu Impact**: Minimal disruption to demand. Customers benefiting from elevated egg prices offsetting costs.
- **2025 Outlook**: Expect top/bottom line growth. HNH and Specialty Products to lead, Animal Nutrition on recovery track.

Actual									0.81	0.85	0.83	0.83	0.87	0.93	0.92	0.85	1.03	1.07	1	0.94	0.94	1.06	1.04	0.95	1.03	1.09	1.03	1.03	1.13	1.17	1.24	1.21
Forecast									0.62	0.5567	0.6625	0.685	0.79	0.82	0.84	0.78	0.82	0.94	0.935	0.8	0.72	0.84	0.97	0.93	0.98	1.035	1.115	1.055	1.045	1.12	1.155	1.175
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+30.65%	+52.69%	+25.28%	+21.17%	+10.13%	+13.41%	+9.52%	+8.97%	+25.61%	+13.83%	+6.95%	+17.50%	+30.56%	+26.19%	+7.22%	+2.15%	+5.10%	+5.31%	-7.62%	-2.37%	+8.13%	+4.46%	+7.36%	+2.98%

BCPC

BCPC fundamentals

BCPC Q4 2025 Earnings

Earnings Call

You can ask Aime

BCPC

BCPC fundamentals

BCPC Q4 2025 Earnings

Earnings Call

BCPC Earnings Call Summary for Q4/202511:00 AM on Feb 20, 2026

BCPC Earnings Call Summary for Q3/202511:00 AM on Oct 21, 2025

BCPC Earnings Call Summary for Q2/202511:00 AM on Jul 31, 2025

BCPC Earnings Call Summary for Q1/202511:00 AM on Apr 24, 2025

BCPC Earnings Call Summary for Q4/202411:00 AM on Feb 21, 2025

You can ask Aime